MINERALYS THERAPEUTICS, INC.

Analyst Reco. Mineralys Therapeutics, Inc.

Equities

MLYS

US6031701013

Market Closed - Nasdaq Other stock markets 21:00:00 23/05/2024 BST			5-day change	1st Jan Change
12.23 ^USD	-2.32%		-7.00%	+42.21%

05-16	Transcript : Mineralys Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 05:01 PM
05-09	Transcript : Mineralys Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Goldman Sachs Initiates Mineralys Therapeutics at Buy With $30 Price Target	04-02	MT
Credit Suisse Adjusts Mineralys Therapeutics' Price Target to $37 From $38, Keeps Outperform Rating	08/08/23	MT
Credit Suisse Adjusts Mineralys Therapeutics' Price Target to $38 From $40, Keeps Outperform Rating	16/03/23	MT
Evercore ISI Starts Mineralys Therapeutics at Outperform	07/03/23	MT
Wells Fargo Starts Mineralys Therapeutics at Overweight With $27 Price Target	07/03/23	MT
Guggenheim Starts Mineralys Therapeutics at Buy With $32 Price Target	07/03/23	MT
BofA Securities Starts Mineralys Therapeutics at Buy With $39 Price Target	07/03/23	MT
Credit Suisse Starts Mineralys Therapeutics at Outperform With $40 Price Target, Says Potential Near-Term Partnership Could Boost Stock Value	07/03/23	MT
Stifel Starts Mineralys Therapeutics at Buy With $45 Price Target	07/03/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

The best tools reserved for subscribers to boost the performance of your investments!

Optimize my profits

fermer